In MS, immune cell patterns differed after Mavenclad

Credibility

Interest

Share:1 min read

Key Takeaway

After cladribine (Mavenclad), immune cell patterns differed between people whose MS stayed stable and those who had relapses.

What They Found

Researchers tracked immune cells and relapses before treatment and after 24 months. T cells, which help direct immune responses, became less varied after treatment. This change was especially clear in people whose MS stayed stable. B cells, another type of immune cell, became more varied after treatment. People who had relapses showed more distinct groups of B cells than people whose MS stayed stable.

Who Should Care and Why

The study followed people with relapsing MS who completed treatment with cladribine (Mavenclad). It compared immune cell patterns in people who had relapses with patterns in those whose MS stayed stable. These patterns may help explain why people had different results after treatment. The study measured immune cells before treatment and after 24 months. It did not test whether these patterns could predict a person's future relapses.

Important Considerations

This study followed 22 people at one center. You cannot tell from this study whether the immune cell changes caused relapses or helped prevent them. The abstract does not report a comparison with people who took a different treatment.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News